BioSpace News Archive

Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that it will release third-quarter 2019 financial results on Wednesday, November 6, 2019, after the close of markets.

EXMceuticals Inc. (CSE: EXM) (FSE: A2PAW2) (the “Company” or “EXM”), a cultivator and producer of high-grade cannabis is pleased to announce that it has obtained the licence for cannabis research and development from INFARMED, the Portuguese National Authority of Medicines and Health Products

Kineticos Life Sciences announces the further expansion of their senior leadership team with the addition of Dan McCormick, Senior Vice President, Biopharma Practice.

Nova Medical Centers, the nation’s leading pure occupational medicine provider, announced today that Dr. Samantha Toews, PT, DPT. has been named as its Vice President of Center Operations.

Carrot Fertility, the leading global fertility benefits provider for employers, announced today that Co-founder and Chief Medical Officer (CMO) Dr. Asima Ahmad has been appointed as Vice-Chair of The Access to Care Special Interest Group by The American Society for Reproductive Medicine (ASRM).

The market will accelerate at a CAGR of over 7% between 2019-2023

MMS Holdings announced that its Executive Director of Global Operations Michelle Gayari has joined the advisory board for the international 501 charity Together Educating All Children in Hospitals As its sole board member in the state of Michigan, Gayari will provide leadership, guidance, and fundraising support to help in bringing exciting, hands-on educational programs to children in hospitals.

eHealth’s survey also shows that prescription drug costs are the number one factor driving purchasing decisions for a third of Medicare consumers

New Research Reveals Broad-Based Anti-Inflammatory Potential of Serotonin 2A Receptor Agonists at Inaugural Scientific Meeting

Segal Trials, a privately held network of research sites throughout South Florida and South Carolina conducting Phase I–IV trials, has been named one of seven sites to begin a Phase II study of psilocybin—a psychedelic prodrug compound—for major depressive disorder (MDD).